Serum Level of PD-1, PD-L1, and PD-L2 as a New Biomarker for Esophageal Cancer

被引：1
|
作者：
Akutsu, Yasunori [1 ]
Murakami, Kentaro [1 ]
Hanari, Naoyuki [1 ]
Kano, Masayuki [1 ]
Uesato, Masaya [1 ]
Ota, Takumi [1 ]
Suito, Hiroshi [1 ]
Matsumoto, Yasunori [1 ]
Takahashi, Masahiko [1 ]
Matsubara, Hisahiro [1 ]
机构：
[1] Chiba Univ, Grad Sch Med, Frontier Surg, Chiba, Japan
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2015年 / 110卷
关键词：
D O I：
10.14309/00000434-201510001-01622
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1622
引用
收藏
页码：S694 / S694
页数：1
相关论文
共 50 条
  • [31] The PD-1 pathway in systemic lupus erythematosus: The Ligands of PD-1, PD-L1 and PD-L2, are also susceptibility factors.
    Abelson, AK
    Johansson, C
    Kozyrev, S
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S203 - S203
  • [32] Determination of PD-L1 positive CETCs as a biomarker for PD-1/PD-L1 treatment monitoring
    Pizon, M.
    Schott, D.
    Pachmann, U.
    Pachmann, K.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 89 - 89
  • [33] Clinical Value of the PD-1/PD-L1/PD-L2 Pathway in Patients Suffering from Endometriosis
    Suszczyk, Dorota
    Skiba, Wiktoria
    Zardzewialy, Witold
    Pawlowska, Anna
    Wlodarczyk, Karolina
    Polak, Grzegorz
    Tarkowski, Rafal
    Wertel, Iwona
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (19)
  • [34] Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer
    Cheng, Chao
    Zhuge, Lingdun
    Xiao, Xin
    Luan, Siyuan
    Yuan, Yong
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [35] PD-1, PD-L1, and PD-L2 Gene Expression and Tumor Infiltrating Lymphocytes in Canine Melanoma
    Stevenson, Valentina B.
    Perry, Samantha N.
    Todd, Michelle
    Huckle, William R.
    LeRoith, Tanya
    VETERINARY PATHOLOGY, 2021, 58 (04) : 692 - 698
  • [36] Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2
    Zak, Krzysztof M.
    Grudnik, Przemyslaw
    Magiera, Katarzyna
    Domling, Alexander
    Dubin, Grzegorz
    Holak, Tad A.
    STRUCTURE, 2017, 25 (08) : 1163 - 1174
  • [37] EXPRESSION OF PD-1, PD-L1 AND PD-L2 IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND ITS CLINIC RELATIONSHIP
    Geng, S.
    Weng, J.
    Deng, C.
    Li, M.
    Lu, Z.
    Wu, P.
    Huang, X.
    Lai, P.
    Du, X.
    LEUKEMIA RESEARCH, 2017, 55 : S112 - S112
  • [38] High-affinity PD-1 molecules deliver improved interaction with PD-L1 and PD-L2
    Li, Yanyan
    Liang, Zhaoduan
    Tian, Ye
    Cai, Wenxuan
    Weng, Zhiming
    Chen, Lin
    Zhang, Huanling
    Bao, Yifeng
    Zheng, Hongjun
    Zeng, Sihai
    Bei, Chunhua
    Li, Yi
    CANCER SCIENCE, 2018, 109 (08): : 2435 - 2445
  • [39] Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
    Bai, Jie
    Gao, Zhitao
    Li, Xiang
    Dong, Liang
    Han, Weidong
    Nie, Jing
    ONCOTARGET, 2017, 8 (66) : 110693 - 110707
  • [40] Evaluation of PD-L1, PD-L2, PD-1 and cytotoxic immune response in oral lichen planus
    Costa, Nadia Lago
    Goncalves, Julie Ane Maria
    de Lima, Sara Lia Goncalves
    de Arruda, Jose Alcides Almeida
    Miranda, Ana Carolina Campos
    Mesquita, Ricardo Alves
    da Silveira, Ericka Janine Dantas
    Batista, Aline Carvalho
    ORAL DISEASES, 2020, 26 (06) : 1246 - 1254
12345